Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium (WE-FiERCE)

NCT06073184 is registered in ClinicalTrials.gov with GynOncTrials as lead sponsor.

NCT NCT06073184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06073184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium (WE-FiERCE)
Lead sponsor
GynOncTrials
Phase
Phase 2
Overall status
Recruiting
Start date
September 17, 2026
Completion date
February 29, 2032
Enrollment
71 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atypical hyperplasia, endometrial cancer, fertility perservation